Search results for " siRNA"

showing 8 items of 38 documents

Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications

2019

In the last years the rapid development of Nucleic Acid Based Drugs (NABDs) to be used in gene therapy has had a great impact in the medical field, holding enormous promise, becoming “the latest generation medicine” with the first ever siRNA-lipid based formulation approved by the United States Food and Drug Administration (FDA) for human use, and currently on the market under the trade name Onpattro™. The growth of such powerful biologic therapeutics has gone hand in hand with the progress in delivery systems technology, which is absolutely required to improve their safety and effectiveness. Lipid carrier systems, particularly liposomes, have been proven to be the most su…

liposomes0303 health sciencesclinical trialsNABDsComputer sciencelcsh:RS1-441Pharmaceutical Science02 engineering and technologyLimitingReview021001 nanoscience & nanotechnologylcsh:Pharmacy and materia medicaClinical trialFood and drug administration03 medical and health sciencesHuman useRisk analysis (engineering)siRNAProduction (economics)NABDs; SiRNA; Liposomes; Clinical trials0210 nano-technology030304 developmental biologyPharmaceutics
researchProduct

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma

2017

Given the paucity of druggable mutations in high-risk neuroblastoma (NB), we undertook chromatin-focused small interfering RNA and chemical screens to uncover epigenetic regulators critical for the differentiation block in high-risk NB. High-content Opera imaging identified 53 genes whose loss of expression led to a decrease in NB cell proliferation and 16 also induced differentiation. From these, the secondary chemical screen identified SETD8, the H4K20me1 methyltransferase, as a druggable NB target. Functional studies revealed that SETD8 ablation rescued the pro-apoptotic and cell-cycle arrest functions of p53 by decreasing p53K382me1, leading to activation of the p53 canonical pathway. I…

p530301 basic medicineCancer ResearchSmall interfering RNAMethyltransferaseCellular differentiationDruggabilityBiologyArticleEpigenesis GeneticNeuroblastoma03 medical and health sciences0302 clinical medicineNeuroblastomamedicineHumansEpigeneticsRNA Small InterferingGeneCell ProliferationsiRNA screenCell growthQuinazolineCell DifferentiationdifferentiationHistone-Lysine N-Methyltransferasemedicine.diseaseSETD8030104 developmental biologyOncology030220 oncology & carcinogenesisQuinazolinesCancer researchdifferentiation; epigenetics; neuroblastoma; p53; SETD8; siRNA screen; Oncology; Cell Biology; Cancer ResearchTumor Suppressor Protein p53epigeneticHuman
researchProduct

Induction of body weight loss through RNAi-knockdown of APOBEC1 gene expression in transgenic rabbits

2014

In the search of new strategies to fight against obesity, we targeted a gene pathway involved in energy uptake. We have thus investigated the APOB mRNA editing protein (APOBEC1) gene pathway that is involved in fat absorption in the intestine. The APOB gene encodes two proteins, APOB100 and APOB48, via the editing of a single nucleotide in the APOB mRNA by the APOBEC1 enzyme. The APOB48 protein is mandatory for the synthesis of chylomicrons by intestinal cells to transport dietary lipids and cholesterol. We produced transgenic rabbits expressing permanently and ubiquitously a small hairpin RNA targeting the rabbit APOBEC1 mRNA. These rabbits exhibited a moderately but significantly reduced …

perte de poidsobesityApolipoprotein BAgricultural BiotechnologyGene Expressionlcsh:MedicinetransgenesisSmall hairpin RNAAnimals Genetically Modified0302 clinical medicinesirnaRNA interferenceGene expressionGene Knockdown TechniquesBiologie de la reproductionMedicine and Health SciencesTransgenesIntestinal MucosaRNA Small Interferinglcsh:Science[SDV.BDD]Life Sciences [q-bio]/Development Biology2. Zero hunger0303 health sciencesGene knockdownReproductive BiologyMultidisciplinarybiologyGenetically Modified OrganismsBiologie du développementapobec1; obesity; editing apob; apob100; apob48; chylomicron; intestine; rabbit; sirna; transgenesis; knockdownchylomicronknockdownAgricultureInherited Metabolic DisordersDevelopment BiologyobésitéCholesterolPhenotypeTransgenic Engineering[ SDV.BDLR ] Life Sciences [q-bio]/Reproductive BiologyLiverapobapob48Gene Knockdown Techniquesanimal transgéniqueRNA Interferencelipids (amino acids peptides and proteins)RabbitsGenetic EngineeringResearch ArticleBiotechnologyexpression géniqueTransgeneAPOBEC-1 DeaminaseMolecular Sequence DatarabbitDiet High-Fat03 medical and health sciencesintestinCytidine DeaminaseWeight Loss[SDV.BDD] Life Sciences [q-bio]/Development BiologyAnimalsHumanslapinRNA Messenger[ SDV.BDD ] Life Sciences [q-bio]/Development BiologyintestineTriglycerides[SDV.BDLR] Life Sciences [q-bio]/Reproductive Biology030304 developmental biologyapobec1Base SequenceGenetically Modified AnimalsAPOBEC1editinglcsh:RBiology and Life Sciences[SDV.BDLR]Life Sciences [q-bio]/Reproductive BiologyMolecular biologyapob100DyslipidemiaMetabolic Disordersbiology.proteinlcsh:QRNA EditingApolipoprotein B-48030217 neurology & neurosurgery
researchProduct

Improvements in Rational Design Strategies of Inulin Derivative Polycation for siRNA Delivery.

2016

The advances of short interfering RNA (siRNA)-mediated therapy provide a powerful option for the treatment of many diseases, including cancer, by silencing the expression of targeted genes involved in the progression of the pathology. On this regard, a new pH-responsive polycation derived from inulin, Inulin-g-imidazole-g-diethylenetriamine (INU-IMI-DETA), was designed and employed to produce INU-IMI-DETA/siRNA "Inulin COmplex Nanoaggregates" (ICONs). The experimental results showed that INU-IMI-DETA exhibited strong cationic characteristics and high solubility in the pH range 3-5 and self-aggregation triggered by pH increase and physiological salt concentration. INU-IMI-DETA showed as well…

polycationssiRNA deliverySmall interfering RNAPolymers and PlasticsInulinBioengineering02 engineering and technology010402 general chemistry01 natural sciencesBiomaterialschemistry.chemical_compoundDrug Delivery SystemsMaterials ChemistryPolyaminesGene silencingHumansGene SilencingRNA Small Interferingpolycations siRNA delivery inulinRational designInulinBafilomycinRNATransfectionHydrogen-Ion Concentration021001 nanoscience & nanotechnologyEndolysosomePolyelectrolytesEndocytosis0104 chemical scienceschemistryBiochemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug DesignMCF-7 Cellspolycations; siRNA delivery; inulin0210 nano-technologyBiomacromolecules
researchProduct

Polymeric nanoparticles for siRNA delivery: Production and applications

2017

Gene therapy through the use of siRNA and a polymeric carrier are becoming an efficient therapeutic option to conventional pharmaceutical formulations for the treatment of deadly diseases, such as cancer, pulmonary, ocular and neurodegenerative diseases. However, several considerations regarding the stability, formulation, and efficacy have to be faced up until these systems could be considered to be a marketable pharmaceutical products for to extend siRNA application to clinical practice. This review is focused on the key challenges of siRNA therapeutics, with special attention on the faced obstacles and on the formulation-related difficulties, providing a list of requirements needed for o…

siRNA deliveryPolymersPharmaceutical ScienceNanotechnology02 engineering and technologyPolyethylenimine010402 general chemistry01 natural scienceschemistry.chemical_compoundPolyaminesHumansRNA Small InterferingPolyethylenimineChitosanPolymeric non viral vectorInulinChitosan; Inulin; Polyaspartamide; Polyethylenimine; Polymeric non viral vectors; siRNA delivery.Genetic Therapy021001 nanoscience & nanotechnologyPolymeric nanoparticles0104 chemical sciencesClinical PracticePolyaspartamidechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoPolymeric non viral vectorsNanoparticles0210 nano-technologyPeptidessiRNA delivery.
researchProduct

Development of New Targeted Inulin Complex Nanoaggregates for siRNA Delivery in Antitumor Therapy.

2021

Here, a novel strategy of formulating efficient polymeric carriers based on the already described INU-IMI-DETA for gene material whose structural, functional, and biological properties can be modulated and improved was successfully investigated. In particular, two novel derivatives of INU-IMI-DETA graft copolymer were synthesized by chemical functionalisation with epidermal growth factor (EGF) or polyethylenglycol (PEG), named INU-IMI-DETA-EGF and INU-IMI-DETA-PEG, respectively, in order to improve the performance of already described “inulin complex nanoaggregates” (ICONs). The latter were thus prepared by appropriately mixing the two copolymers, by varying each component from 0 to 100 wt%…

siRNA deliveryRNase PCellPharmaceutical Science02 engineering and technology010402 general chemistry01 natural sciencesArticleAnalytical Chemistrylcsh:QD241-441EGF; inulin; PEG; siRNA delivery; targeting; tumourlcsh:Organic chemistryEpidermal growth factorNeoplasmsDrug DiscoveryPEG ratioZeta potentialmedicineCopolymerHumansDoxorubicinPhysical and Theoretical ChemistryRNA Small InterferingtargetingEGFDrug CarriersinulinChemistrytumourOrganic ChemistryTransfection021001 nanoscience & nanotechnologyPEG0104 chemical sciencesNanostructuresmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoChemistry (miscellaneous)BiophysicsMCF-7 CellsMolecular Medicine0210 nano-technologymedicine.drugMolecules (Basel, Switzerland)
researchProduct

Development of different nanosystems for drugs and siRNA delivery

Cancer is one of the leading causes of death in the world. Over the past several decades, the development of engineered nanosystems for targeted drug delivery have received great attention thanks to their possibility to overcome the limitations of classical cancer chemotherapy including poor solubility, targeting incapability, nonspecific action and, consequently, systemic toxicity. In this contest, four different models of nanocarriers have been analysed and compared for their capacity to target tumour tissue and to release the therapeutic agent in a controlled way: INU-EDA-P,C-DOXO; PHEA-EDA-P,C-DOXO; PVP-siRNA and RGO-siRNA. Inulin and PHEA were conjugated to the antineoplastic drug doxo…

siRNA deliverySettore BIO/10 - BiochimicaNanosystems; tumour therapy; drug delivery; siRNA deliverydrug deliveryNanosystemtumour therapy
researchProduct

Inulin Derivatives Obtained Via Enhanced Microwave Synthesis for Nucleic Acid Based Drug Delivery

2015

A new class of therapeutic agents with a high potential for the treatment of different socially relevant human diseases is represented by Nucleic Acid Based Drugs (NABD), including small interfering RNAs (siRNA), decoy oligodeoxynucleotides (decoy ODN) and antisense oligonucleotides (ASOs). Although NABD can be engineered to be specifically directed against virtually any target, their susceptibility to nuclease degradation and the difficulty of delivery into target tissues severely limit their use in clinical practice and require the development of an appropriate nanostructured delivery system. For delivery of NABD, Inulin (Inu), a natural, water soluble and biocompatible polysaccharide, wa…

siRNA deliverymicrowavespermineSettore CHIM/09 - Farmaceutico Tecnologico Applicativopolyplexnucleic acid based drugsInulin; microwave; nucleic acid based drugs; polyplex; siRNA delivery; spermineInulinInulin microwave nucleic acid based drugs polyplex siRNA delivery spermine
researchProduct